Aequus Pharmaceuticals Inc. announced the formation of a strategic advisory board in ophthalmology with the appointment of its first two members, Dr. Ike Ahmed of the Prism Eye Institute joining as Chairman, and Dr. Rosa Braga-Mele of the University of Toronto. Aequus has formed the Advisory Board to assist in assessing and rationalizing the many ophthalmology pipeline opportunities, both in therapeutics and medical devices, available to the Company. The advisory board will help Aequus in determining whether a product can improve patient outcomes, integrate into a clinician’s workflow, and navigate the Canadian reimbursement and commercial landscape. Dr. Ahmed and Dr. Braga-Mele will be working with the Aequus team to add additional members to the Advisory Board over the coming weeks. Dr. Ike Ahmed has become world renowned for his skills and ground-breaking work in the diagnosis and surgical treatment of highly complex eye diseases including glaucoma and surgical complications. He has been at the leading edge of novel treatments for glaucoma, cataract, and lens implant surgery, having performed the first laser cataract surgery in Canada, and designing devices, implants, and techniques for ophthalmic applications. Dr. Braga-Mele is a Professor of Ophthalmology, Faculty of Medicine, at the University of Toronto and the Cataract Director at the Kensington Eye Institute.